Nektar Therapeutics (NKTR) Announced Positive results for Rezpegaldesleukin

Nektar Therapeutics (NASDAQ:NKTR) is one of the Stocks With Huge Catalysts on the Horizon. On June 24, Nektar Therapeutics (NASDAQ:NKTR) announced positive results from the Phase 2b REZOLVE-AD trial of Rezpegaldesleukin to treat moderate-to-severe atopic dermatitis.

The drug showed significant improvement in Eczema Area and Severity Index scores after 16 weeks compared to placebo. Some notable points from the results include a 75% reduction in EASI, itch reduction, body surface area affected, and physician-assessed severity scores. The results highlighted that these improvements appeared quickly after starting treatment, helping differentiate this therapy from existing options.

Nektar Therapeutics (NKTR): Among Stocks Wall Street Is Calling Bullish Amid Market Turmoil

A scientist in lab coat testing a new biopharmaceutical drug on a microscope.

Moreover, Rezpegaldesleukin also led to strong, dose-dependent reductions in inflammatory markers tied to atopic dermatitis, including TARC/CCL17 and IL-19. Management noted that this shows that the treatment works using a unique Treg (regulatory T-cell) mechanism, which could be a first in its class. Nektar Therapeutics plans to present these findings at medical conferences later in 2025, whereas the long-term maintenance data are expected in early 2026.

Nektar Therapeutics is a clinical-stage biotech company developing therapies that target immune system dysfunction in autoimmune, inflammatory diseases, and cancer.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

This article is originally published at Insider Monkey.